Press | ALK

Press

If you are a journalist and have any questions about ALK, please feel free to contact our Media Relations teams.

The press releases in this press room contain information that is of general news value for the press, and available for journalists or media with a view to journalistic assessment and preparation before publication.

 

Latest news

News

  • Post date
    11/19/2026
    ALK presents new data at FAAM-EUROBAT-ISMA 2026: Data from a comparative study using adrenaline trainer devices suggests EURneffy® nasal adrenaline spray is more suitable for public places than an adrenaline auto-injector
  • Post date
    11/17/2026
    Nine-month interim report (Q3) 2026 (unaudited)
  • Post date
    11/16/2026
    ALK to present at the Jefferies Global Healthcare Conference in London
  • Post date
    11/12/2026
    ALK to present positive phase II data on its tablet for the treatment of peanut allergy at ACAAI 2026 
  • Post date
    11/10/2026
    Invitation to the presentation of ALK’s first nine months (Q3) 2026 results on Tuesday, 17 November 2026
  • Post date
    11/02/2026
    Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
Facts and guidelines

 


About ALK


Logo, fonts and images


Contact Media Relations


 

Photo library
Executive Leadership Team

Peter Halling, President & CEO


Claus Steensen Sølje, CFO & EVP Global Business Operations


Edward Jordan, EVP Commercial Operations North America


Flora Beiche-Scholz, EVP Commercial Operations Europe


 


Jacob Glenting, EVP Global Research & Development


Tina Abild Olesen, EVP Corporate, Portfolio and Product Strategy


Lika Thiesen, EVP Global People & Organisation


Christian G. Houghton, EVP Product Supply


Jan Engel Jensen, SVP Global Quality

Headquarters & facilities


ALK headquarters


Production facilities, Hørsholm


Production facilities, Hørsholm


Production facilities, Hørsholm

Last updated: 01.10.2026